Oct. 14 (Fri.) ,2016 15:00-17:00

Annex Hall

Simultaneous Interpretation

Front-line R&D of Regenerative Medicine Products

This session shows projects and technology platforms of the Japanese and foreign companies that are developing Regenerative Medicine products.


Kunihiko Suzuki

Vice-chairman, Forum for Innovative Regenerative Medicine / Member of the Board, Vice Chairman, MEDINET

David W. Smith

Vice President, Global Business Development, Lonza

C-Cure, An Autologous Cell Therapy Targeting Ischemic Heart Failure

Georges Rawadi

VP, Business & Development, Celyad

Cymerus™: Scalable Production of Allogenic, iPSC-derived Mesenchymal Stem Cells (MSCs) for Therapeutic Use

Ross A Macdonald

Managing Director and Chief Executive Officer, Cynata Therapeutics

Near-future Therapy with Cardiovascular Cells Differentiated from iPSCs

Kenji Kakuta

President, iHeart Japan

A Leading Company in the Emerging Field of Cell Replacement Therapy: The Challenges of Developing a Diabetes Cell Therapy Product

Mark Zimmerman

Vice President, Strategy and Business Development, Viacyte

Close Window